Intellia Therapeutics Investor Presentation — August 2019

Document content

Intellia Therapeutics’ Legal Disclaimer

This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia ”)within themeaning ofthePrivate Securities Litigation Reform

Actof1995 .These forward -looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s ability toadvance andexpand

theCRISPR/Cas 9technology todevelop human therapeutic products, aswellasourCRISPR/Cas 9intellectual property portfolio ;ourability toachieve stable

oreffective genome editing ;ourability toeffectively administer onedose ormultiple doses ofourCRISPR/Cas 9product candidates ;thepotential timing and

advancement ofourpreclinical studies, including continuing non-human primate studies forourTransthyretin Amyloidosis (“ATTR”) program andother studies

forourother programs (such as,alpha -1antitrypsin deficiency (“AATD”)), and human clinical trials ;thetiming andpotential achievement ofmilestones to

advance ourpipeline including initiation ofinvestigational new drug (“IND”) -enabling studies and filing INDs ;ourability toreplicate results achieved inour

preclinical studies, including those inourATTR, AATD, primary hyperoxaluria type 1(“PH1”)andWilms’ Tumor 1(“WT 1")/acute myeloid leukemia (“AML”)

programs, inanyfuture studies, including human clinical trials;ourability togenerate data andreplicate results relating toenhancements toourproprietary

lipid nanoparticle (“LNP”) technology, including itsformulation andcomponents, inpreclinical orclinical studies, orthatanyenhancements willresult inan

improved product candidate profile ;thepotential development ofourproprietary LNP-adeno -associated virus (“AAV”) hybrid delivery system toadvance our

complex genome editing capabilities ;thepotential development ofother invivo orexvivo celltherapeutics ofalltypes, andthose targeting WT1inparticular,

using CRISPR/Cas 9technology ;ourability toconduct successful IND-enabling studies ofNTLA -2001 andsubsequently submitting anINDapplication inmid-

2020 ;ourintent togenerate andpresent additional insertion/repair data, andpreclinical data insupport ofourfirstexvivo programs onimmuno -oncology by

theendof2019 ;theintellectual property position andstrategy ofIntellia’s licensors orother parties from which itderives rights, aswellasthird-parties and

competitors ;actions bygovernment agencies ;ourgrowth asacompany andtheanticipated contribution ofthemembers ofourboard ofdirectors andour

executives toouroperations andprogress ;theimpact ofourcollaborations onourresearch anddevelopment programs ;thepotential timing ofregulatory

filings regarding ourdevelopment programs ;thepotential commercialization opportunities, including value and market, forourproduct candidates ;our